Archaeologists in France Discover Giant Roman Gallic Villa Hiding in Plain Sight
A recent excavation reveals that a large building excavated in 1966 was just a part of an even grander ancient complex.
In 1966, archaeologists in France uncovered an ancient 7,535-square-foot building near the town of Auxerre. Remains of furniture in the edifice's ten rooms led archaeologists to estimate that it was inhabited from the first to the fourth century CE, and evidence of mosaics and floor heating indicated that the inhabitants were members of a wealthy social class. But it turns out that these spaces were a small part of an even grander dwelling.
Archaeologists have revealed that the building excavated almost six decades ago is just a secondary wing of a luxurious 43,056-square-foot villa—one of the largest known Roman villas in modern-day France.
According to an agricultural treatise by the ancient Roman writer Lucius Junius Moderatus Columella called De Re Rvstica, Roman villas were divided into three main sections: the pars urbana, where the landowner and his family lived; the pars rustica, which housed the workers, animals, and farming tools; and the pars fructuaria for the harvest tools. The excavation near Auxerre has thus far revealed the complex's residential pars urbana, along with some features that may have belonged to the pars rustica.
The building wrapped around a square garden, with a basin at one end and a fountain at the other. The chambers surrounding the garden included spaces to receive guests, technical rooms, and possible a kitchen, and the eastern wing of the building showcased thermal baths. The space that may have belonged to the pars rustica section of the complex consists of a rectangular space near a boundary wall that encircles part of the villa.
In a statement by France's National Institute for Preventive Archaeological Research (Inrap), archaeologists suggest the villa was built in two or three stages. Further research will be necessary to determine the building's potential association with ancient Auxerre, known as Autessiodurum, which became a prominent city in the fourth century.
By the mid first century BCE, future Roman dictator-for-life Julius Caesar had conquered all of Gaul, a region including most of modern day France and Belgium. Large Roman Gallic villas traditionally had richly developed pars urbana and almost always included private thermal baths. They also usually incorporated fountains, gardens, private sanctuaries, and elaborate interiors featuring marble, frescoes, and mosaics for the enjoyment of their wealthy landowners, who made up the region's political elite.
The recently uncovered estate represents one of the largest Roman villas in Gaul, according to The History Blog. It remains to be seen what further insight the magnificent remains will provide into the lives of Gaul's wealthiest ancient residents. In the meantime, visitors will have the rare opportunity to tour the site on June 15 in honor of European Archaeology Days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Asteroid 2024 YR4 might smash into the moon
Earlier this year, astronomers alerted the world to a startling possibility: based on initial calculations, it appeared that a recently discovered asteroid known as 2024 YR4 had a not-zero chance of colliding with Earth in 2032. At 174–220 feet wide, the space rock has the potential to destroy a sizable city in less than a decade's time. In this case, however, 'not-zero' never amounted to anything higher than a three percent probability. And after gathering additional information from an array of terrestrial observatories as well as the James Webb Space Telescope, experts concluded in March that 2024 YR4 didn't pose any direct threat to the planet. But just because Earth was spared doesn't mean our moon is safe. Based on the most recent calculations, the chance that the asteroid has a 2032 date with the lunar surface is higher than it ever was for us. 'The probability that asteroid 2024 YR4 will strike the Moon on 22 December 2032 is now approximately 4 percent, and this probability was still slowly rising as the asteroid faded out of view,' the European Space Agency said in its most recent update. Okay, so it's not that much more likely than 2024 YR4's highest probability for Earth. But a 96-percent likelihood of missing the moon leaves room for the space rock to defy the odds. Astronomers will now need to wait until its orbit sends it around the sun in mid-2028 to begin conducting further observations. So what happens if 2024 YR4 really does collide with the moon? That's a great question—one that even the experts can't answer at the moment. 'No one knows what the exact effects would be,' admitted ESA Planetary Defense Office director Richard Moissl. 'It is a very rare event for an asteroid this large to impact the Moon—and it is rarer still that we know about it in advance.' Moissl added the collision 'would certainly leave a new crater on the surface,' but it's not currently possible to accurately predict how much material would eject into space, and whether Earth's gravitational pull would catch any of it. That said, there isn't a major worry that an asteroid of 2024 YR's size would result in lunar armageddon. Moissl also explained that while the impact would likely be visible from Earth, astronomers remain 'excited by the prospect of observing and analyzing it.' If you're still uneasy about errant asteroids hurtling towards us, take comfort in knowing that international space agencies are working to improve our early detection capabilities and plan for worst-case scenarios. The ESA, for example, is currently planning to launch its Near-Earth Object Mission in the Infrared (NEOMIR) satellite in the early 2030s. NEOMIR is designed to position itself at the first Sun-Earth Lagrange Point, one of five locations where the planet's gravitational forces and the satellite's orbit interact to allow for a stable observation point. Once there, the array will be able to scan for unknown asteroids larger than 197-feet-wide that are potentially en route to Earth. This will provide governments and agencies much more time to identify, analyze, and plan for space emergencies. 'NEOMIR would have detected asteroid 2024 YR4 about a month earlier than ground-based telescopes did,' Moissl explained. 'This would have given astronomers more time to study the asteroid's trajectory and allowed them to much sooner rule out any chance of Earth impact in 2032.'
Medscape
6 hours ago
- Medscape
Efgartigimod Use Extends to Myositis, Sjögren Disease
BARCELONA, Spain — Efgartigimod could have a role to play in the treatment of both myositis and Sjögren disease, according to data from two 'proof-of-concept' phase 2 studies reported at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. In the ALKIVIA study, involving 89 adults with active idiopathic inflammatory myopathy (IMM), significantly greater clinical improvement in muscle strength and physical function — as measured by the 2016 American College of Rheumatology (ACR)/EULAR Myositis Response Criteria's Total Improvement Score (TIS) — was achieved with efgartigimod than with placebo. The least-squares mean TIS at week 24 was 50.45 in the efgartigimod arm vs 35.65 in the placebo arm (P = .0004). There was also a significant improvement in mean TIS over time. In the RHO study, a significantly greater proportion of the 23 adults with primary Sjögren disease treated with efgartigimod achieved the trial's primary endpoint — a clinical response in at least three of five items using the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) measure — than did the 11 adults given a placebo. At week 24, 45.5% of efgartigimod-treated individuals vs 11.1% of the placebo-treated participants met this primary endpoint of the trial. Addressing Unmet Needs IMM and Sjögren disease are two rheumatic and musculoskeletal diseases lacking effective treatments; targeting Immunoglobulin G (IgG) autoantibodies with efgartigimod was of interest, said both of the presenting investigators for the two studies at the meeting. Hector Chinoy, MD Hector Chinoy, MD, a consultant rheumatologist for Salford Royal Hospital and professor of rheumatology and neuromuscular disease at the University of Manchester, England, said during his presentation of the ALKIVIA study findings that, with regard to IMM, 'We use too [many] steroids. We need a steroid-sparing profile, one providing a sustained response for both muscle and extra muscular involvement.' Isabelle Peene, MD, of Ghent University Hospital and the VIB Center for Inflammation Research, both in Ghent, Belgium, said in her presentation of the RHO study data: 'The most prominent autoantibodies in Sjögren's are, of course, those against Rho52, Rho60, and SSB. As there is a high unmet need in Sjögren's, we wondered whether the mode of action of efgartigimod could alter this disease course.' Blocking Antibody Recycling The data from the two studies looked 'very promising,' Elizabeth Price, MBBCh, PhD, a consultant rheumatologist who works at Great Western Hospitals NHS Foundation Trust, Swindon, England, told Medscape Medical News. Price, who has a specialist interest in Sjögren disease, said, 'Efgartigimod is one of a new class of monoclonal antibodies targeting the [IgG1] neonatal Fc receptor [FcRn]. This receptor is involved in binding circulating immunoglobulins and transporting them across membranes (including the placenta).' The drug, which had already gained regulatory approval in the US and some other countries for use in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, worked by reducing the level of IgG and other pathogenic autoantibodies. By binding to FcRn, efgartigimod essentially blocked the ability for IgG to be recycled back into the circulation, and thus IgG levels were reduced without having an impact on antibody production in general, it was reported. The ALKIVIA Study ALKIVIA was an ongoing trial, Chinoy explained; a 52-week phase 3 component was continuing from the phase 2 results he presented. The trial recruited people with several subtypes of IMM, including dermatomyositis, immune-mediated necrotizing myositis, polymyositis, or antisynthetase syndrome. Participants were randomly allocated 1:1 to treatment with efgartigimod or placebo in addition to background IMM treatment. Those in the efgartigimod arm received a 1000 mg dose given subcutaneously once a week. Baseline characteristics reflected 'a typical profile of a myositis patient,' Chinoy said, and generally were comparable between the groups. Overall, the mean age was 56.6 years, and the median time since diagnosis was 4.4 years. Just over 75% were women, and 72% were White. Chinoy noted that, in addition to higher TIS in the efgartigimod vs the placebo arm after 24 weeks, significantly more participants taking efgartigimod achieved TIS improvements of ≥ 20 (91.5% vs 73.8%, P = .025), ≥ 40 (78.7% vs 47.6%, P = .0029), and ≥ 60 (34.0% vs 9.5%, P = .0055), signifying mild, moderate, or major clinical improvement, respectively. Clinical improvement occurred more quickly in the efgartigimod than in the placebo arm, with minimal improvement seen at a respective 30 vs 72 days (P = .002) and moderate improvement after 113 days vs not estimable (P = .029). As for safety, similar percentages of efgartigimod-treated (87%) and placebo-allocated (88%) participants experienced at least one adverse event. Most adverse events occurring with efgartigimod were related to its mode of administration, with injection site bruising, redness, pain, or other reactions recorded. There were fewer grade 3 or higher adverse events in the efgartigimod arm than in the placebo arm (14.9% vs 28.6%). Two deaths occurred with efgartigimod but none with placebo. Neither death was attributed to the drug; one involved a road traffic accident and the other was a case of preexisting liver cirrhosis that had 'only really come to light during the course of the study,' said Chinoy. Questioning the Data Ronald van Vollenhoven, MD, PhD, of Amsterdam UMC and Amsterdam Rheumatology and Immunology Center ARC, Netherlands, said after Chinoy's presentation that 'this approach of lowering total IgG is very interesting.' He questioned, however, whether the drug could actually be targeting pathogenic antibodies vs endogenous immunoglobulins, 'which obviously serve a useful purpose.' Richard Alan Furie, MD, of Northwell Health in New York, New York, said he thought problems with placebo response rates had been seen in lupus, and he asked, 'What do you think the reasons are for high placebo response rates in myositis, and what is being done about it?' Chinoy responded: 'Patients were allowed to be on background treatment; they could be on up to 20 mg of prednisolone at inclusion into the study.' The baseline data showed that 82.0% had been treated with systemic corticosteroids, and more than three-quarters had received disease-modifying antirheumatic drugs. This background treatment, along with some geographical variation that was noted in the TIS responses, was probably behind the high placebo response rate, Chinoy said. 'I think for future trials, we may be looking for a more stringent endpoint, for primary endpoints,' he added. The RHO Study The design of the RHO study was slightly different. It was a phase 2 study that was not designed to run directly into a phase 3 trial; randomization to efgartigimod or placebo was 2:1 rather than 1:1; and efgartigimod was given once weekly at a 10 mg/kg intravenous dose rather than subcutaneously. Participants enrolled in the study had to meet the following criteria: a diagnosis of Sjögren disease as per ACR/EULAR 2016 criteria within the past 7 years, an EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) ≥ 5, positive test for anti-Ro/SS-A antibodies, and residual salivary flow. Three of the 34 people who were randomized did not meet these eligibility criteria, however, and were not included in the efficacy analysis, Peene reported. Although baseline demographic data were fairly typical for Sjögren disease — almost all participants were female — Peene acknowledged after questioning that there were some differences between the groups. For example, the median age was 49 years in the efgartigimod group and 58 years in the placebo group, and the median clinical ESSDAI scores were 13 vs 18. 'It's a very small study,' Peene said. 'We just wanted to have [an] idea of, is it working? And what's the estimate of the treatment effect? But I agree that this is a little bit skewed.' Alongside CRESS, another relatively new outcome measure was used, the Sjögren's Tool for Assessing Response (STAR). Results showed that 54.5% of efgartigimod-treated vs 33.3% of placebo-allocated participants had a score of score ≥ 5, which was the threshold needed to be a responder. No relevant changes in the EULAR Sjögren's Syndrome Patient Reported Index score were observed. But there were improvements in clinical ESSDAI total scores (-7.0 vs -4.0), which will be the primary endpoint in the follow-up phase 3 trial called UNITY. Efgartigimod was also shown to reduce mean levels of both IgG (by 58%) and anti-Ro52 autoantibodies (by 64%) vs baseline to week 4 onward. By comparison, IgG levels were more or less unchanged in the placebo arm, and anti-Ro52 autoantibodies had increased by just under 40% from baseline. There were also reductions in rheumatoid factor and complement component 1q seen with efgartigimod but not placebo. At least one adverse event occurred in 87% of participants taking efgartigimod and 64% of those given placebo. No grade 3 or higher or fatal adverse events were observed. One adverse event in the efgartigimod arm led to discontinuation, but this was not related to the study drug, Peene said. The most common adverse events — which occurred more often in the efgartigimod than in the placebo arm — were headache (17% vs 9%), nasopharyngitis (17% vs 9%), influenza (13% vs 0%), and urinary tract infection (13% vs 9%). Promising Results, but More Data Required Both the RHO and ALKIVIA studies were picked by Helga Lechner-Radner as part of her clinical highlights of the meeting. During the EULAR 2025 Highlights session, Lechner-Radner, a senior physician at the Medical University of Vienna, Austria, said: 'We need more data; the phase 3 [trials] of this compound [are] currently underway and we really look forward to [their results].' The ALKIVIA and RHO studies were funded by argenx; study authors included employees of the company. Chinoy reported relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Isabelle Peene acknowledged working with argenx and BMS. Bowman told Medscape Medical News he has been brought in as an independent consultant and was not an investigator for the UNITY study. Price, van Vollenhoven, and Furie had no relevant conflicts of interest to disclose. Sara Freeman is a freelance medical journalist based in London, UK.
Gizmodo
8 hours ago
- Gizmodo
‘Leviathan' Is a Steampunk Anime Soaring With Heart, Even if Its Animation Grounds It
While anime remakes and manga adaptations, along with the occasional original project, continue to dominate the medium, a quieter trend has begun to emerge: the adaptation of Western novels. The latest addition to this movement is Scott Westerfeld's 2009 steampunk historical fiction novel, Leviathan, reimagined as a 3DCG anime by Studio Orange in partnership with Qubic Pictures of Star Wars: Visions fame. Though the 12-episode anime doesn't quite recapture the visual splendor of the studio's earlier landmarks, its deft political narrative, confident scripting, and stirring score carry it through as a prescient and worthwhile adaptation. Set in an alternate history of World War I, Leviathan's backdrop includes the added intersection of steampunk warfare and speculative sci-fi. The background tapestry of the anime features an additional conflict between 'Darwinists'—nations that wield genetically engineered beasts, such as jellyfish airships and living whale zeppelins—and 'Clankers,' industrial superpowers relying on giant mechs and futuristic machines to wage war. One half of the heart of Leviathan is Alek, a fugitive prince and heir to the Austro-Hungarian throne, thrust into political exile alongside his tutors following the assassination of his father—an event that serves as the flashpoint for the global war. Naïve but well-meaning, Alek must navigate the space between royal nobility and survival under the guidance of his contrasting mentorships' tug-of-war rearing him toward warm charitability and cold pragmatism. As Europe ignites behind him, Alek travels, concealing his identity while struggling to reconcile the weight of his lineage with his inexperience with the world. The other half of Leviathan's beating heart is Deryn Sharp, a headstrong Scottish girl who pretends to be a boy so she can enlist in the British air service—not out of patriotic duty, but in pursuit of the freedom to fly the skies in a world that otherwise would deny her that liberty. When their paths converge aboard the living whale airship of the HMS Leviathan, the unlikely duo embark on a coming-of-age odyssey, deepening their bond and challenging the boundaries of their friendship-turned-Mulan-esque romance as they pursue their shared desire to take control of their destinies. Leviathan's story beautifully explores the chemistry between its characters, capturing the essence of an ensemble-driven storytelling reminiscent of series like Avatar: The Last Airbender. However, its narrative is rooted in steampunk grit rather than spiritual mysticism, and it takes some time for the show to gain its momentum. Visually, however, the series lands in a curious middle ground, where it's competent but far from arresting. Studio Orange, while no stranger to excellent CG animation with shows like The Land of the Lustrous, Beastars, and Trigun Stampede, feels unusually restrained. Leviathan feels like Orange is coloring within the lines of its source material rather than pushing against its borders. The mech and creature designs are impressively detailed on a static level, but in motion, the animation often feels hemmed in. As a result, these technical limitations make Leviathan feel like it was brought to life by video game cutscene logic that occasionally has to tighten its belt to make the magic happen rather than a fully realized, kinetic spectacle. Ironically, the most consistently striking visuals in Leviathan aren't found within its episodes but in its watercolor-style ending credits. These closing sequences showcase concept art of key moments from its concluded episodes with such vivid color, spatial depth, and expressive character work that they feel like glimpses into a more dynamic version of the show where every frame bursts with energy that its episodes only seem to hint at in retrospect. As if shooting itself in the foot, Leviathan's end credits are a bittersweet flourish that, while intended to highlight the wonder of how its anime brought its storyboards to life, underscores the pang of what could've been. Despite its visual shortcomings, Leviathan's production has notable successes. Chief among them is the quietly luminous opening and ending theme composed by the legendary Joe Hisaishi (known for works like Spirited Away and Castle in the Sky), along with a score by Nobuko Toda and Kazuma Jinnouchi (who have worked on Suzume, Ghost in the Shell SAC_2045, and Metal Gear Solid 4). Hisaishi's musical contributions, in particular, elevate the series with a delicate emotional resonance. His music enriches even the simplest scenes with unexpected depth and enhances battles with powerful acclaim. Notably, his opening theme, 'Paths Combine,' serves both as an overture and a musical promise, suggesting that although the show's animation may occasionally falter, its storytelling will remain strong off the muscle of Hisaishi's orchestration. While Leviathan leans on the literary strength of its source material, its narrative doesn't necessarily reinvent the wheel of sprawling historical fiction. Familiar story beats like double crosses, tragic losses, and a slow unfurling romance are all telegraphed well in advance. Yet the series finds its footing in how its characters respond to these turns with surprising intelligence and emotional sincerity, keeping things engaging. Even when it dips into dramatic irony territory—most notably as its leads keep secrets from one another—Leviathan doesn't string viewers along beyond reason. Instead, it grants each development an emotional payoff that makes even the most predictable arcs along Alek and Deryn's sprawling journey feel emotionally earned. While Leviathan may not reach the soaring heights of its titular sky whale, it maintains a steady altitude through earnest storytelling and immersive worldbuilding. In a genre often overrun by bombastic spectacle or overwrought melodrama, the series offers something quieter but no less resonant—a contemplative tale of identity, duty, and self-determination in a world bracing for collapse. What elevates it isn't just its ambition, but its willingness to admit uncertainty—a story that understands it doesn't need all the answers to be worth the journey. Whether you're a history buff drawn to a whimsical remix of WWI or a younger viewer discovering that those who shape history aren't always the ones etched into it, Leviathan offers a digestible and reflective tale that challenges the notion that power alone defines right and embraces a narrative fueled by empathy and self-determination in its stead. While imperfect, Leviathan is a heartfelt series that rises above its visual shortcomings through strong writing, a resonant thematic core, and the compelling bond between its leads, determined to forge a different path from the one laid before them by their predecessors. Leviathan premieres on Netflix July 10. Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
